KFAS
ADMA icon

Keating Financial Advisory Services’s ADMA Biologics ADMA Stock Holding History

Keating Financial Advisory Services’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.7K Sell
801
-1,158
-59% -$10.6K ﹤0.01% 1416
2026
Q1 		$17.7K Sell
1,959
-20,716
-91% -$327K ﹤0.01% 938
2025
Q4 		$414K Buy
+22,675
New +$382K 0.06% 243

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Keating Financial Advisory Services's ADMA Position: Q2 2026 in Review

Keating Financial Advisory Services reduced its ADMA Biologics (ADMA) stake by 59% in Q2 2026, selling an estimated $10.6K and leaving 801 shares worth $6.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1416.

Keating Financial Advisory Services first reported a position in ADMA in Q4 2025 and has held it in 3 quarters since. The position peaked at $414K in Q4 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Keating Financial Advisory Services held 801 shares of ADMA Biologics worth $6.7K as of Q2 2026.
  • Keating Financial Advisory Services sold 1,158 ADMA Biologics shares in Q2 2026, an estimated $10.6K.
  • ADMA Biologics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1416 holding.
  • Keating Financial Advisory Services first reported a position in ADMA Biologics in Q4 2025 and has held it in 3 quarters since.
  • Keating Financial Advisory Services's ADMA Biologics position peaked at $414K in Q4 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.